Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults
Steady-State Pharmacokinetic Interaction Study of Indinavir and Rifabutin
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
A PHASE1 clinical study on HIV Infections, this trial is completed. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 6 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Nov 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Baltimore, United States
- • Denver, United States
- • Indianapolis, United States
- • Los Angeles, United States
- • Miami, United States
- • New York, United States